This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Salud financiera de hoja de balance de ProSomnus

Salud financiera controles de criterios 0/6

ProSomnus tiene un patrimonio de los accionistas total de $-26.6M y una deuda total de $32.8M, lo que sitúa su ratio deuda-patrimonio en -123.2%. Sus activos y pasivos totales son $26.3M y $52.9M respectivamente.

Información clave

-0.4%

Ratio deuda-patrimonio

US$158.00k

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	US$4.61m
Patrimonio	-US$37.47m
Total pasivo	US$63.88m
Activos totales	US$26.40m

Actualizaciones recientes sobre salud financiera

Recent updates

Positive Sentiment Still Eludes ProSomnus, Inc. (NASDAQ:OSA) Following 35% Share Price Slump

Feb 22

ProSomnus, Inc.'s (NASDAQ:OSA) Shares Leap 60% Yet They're Still Not Telling The Full Story

Dec 20

Análisis de la situación financiera

Pasivos a corto plazo: OSAP tiene patrimonio neto negativo. Es una situación más grave que activos a corto plazo que no cubren pasivos a corto plazo.

Pasivo a largo plazo: OSAP tiene patrimonio neto negativo. Esta situación es más grave que el hecho de que los activos a corto plazo no cubran los pasivos a largo plazo.

Historial y análisis de deuda-patrimonio

Nivel de deuda: OSAP tiene patrimonio negativo, una situación más grave que un alto nivel de endeudamiento.

Reducción de la deuda: OSAP tiene patrimonio neto negativo, por lo que no necesitamos comprobar si su deuda se ha reducido con el tiempo.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: OSAP.Q tiene menos de un año de cash runway basado en su flujo de caja libre actual.

Pronóstico de cash runway: OSAP.Q tiene menos de un año de cash runway si el flujo de caja libre sigue reduciéndose a tasas históricas de 47% cada año

This company listing is no longer active

Salud financiera de hoja de balance de ProSomnus

Salud financiera controles de criterios 0/6

Información clave

Actualizaciones recientes sobre salud financiera

ProSomnus, Inc. Emerged from Bankruptcy

ProSomnus, Inc. Emerged from Bankruptcy

Second Amended Joint Reorganization Plan Approved for ProSomnus, Inc.

First Amended Disclosure Statement Approved for ProSomnus, Inc.

First Amended Reorganization Plan & Disclosure Statement Filed by ProSomnus, Inc.

First Amended Reorganization Plan & Disclosure Statement Filed by ProSomnus, Inc.

Recent updates

ProSomnus, Inc. Emerged from Bankruptcy

ProSomnus, Inc. Emerged from Bankruptcy

Second Amended Joint Reorganization Plan Approved for ProSomnus, Inc.

First Amended Disclosure Statement Approved for ProSomnus, Inc.

First Amended Reorganization Plan & Disclosure Statement Filed by ProSomnus, Inc.

First Amended Reorganization Plan & Disclosure Statement Filed by ProSomnus, Inc.

ProSomnus, Inc. announced delayed 10-Q filing

Prosomnus Contributes Two Scientific Abstracts Accepted for Presentation At the 2024 American Academy of Dental Sleep Medicine Annual Meeting

Motion for Joint Administration Filed by ProSomnus, Inc.

ProSomnus, Inc. Filed for Bankruptcy

Nasdaq Files A Form 25 with the SEC to Remove ProSomnus, Inc.'s Securities from Listing

New major risk - Share price stability

ProSomnus, Inc.(OTCPK:OSAP) dropped from NASDAQ Composite Index

New major risk - Market cap size

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

ProSomnus Provides Non-Compliance Update

Prosomnus Reports Successful Pilot Study Validation of Next Generation Remote Patient Monitoring Device for Obstructive Sleep Apnea

Positive Sentiment Still Eludes ProSomnus, Inc. (NASDAQ:OSA) Following 35% Share Price Slump

ProSomnus, Inc. to Report Q4, 2023 Results on Mar 18, 2024

ProSomnus, Inc. Submits a Hearing Request to the Panel on February 16, 2024 to Appeal the Staff's Delisting Determination

ProSomnus, Inc. Severe Indication 510(K) Submission Accepts for Review by the Fda

ProSomnus, Inc.'s (NASDAQ:OSA) Shares Leap 60% Yet They're Still Not Telling The Full Story

Consensus EPS estimates fall by 36%

New major risk - Financial position

Third quarter 2023 earnings: EPS misses analyst expectations

New major risk - Market cap size

ProSomnus Receives A Notification Letter from Listing Qualifications Department of Nasdaq

ProSomnus, Inc. to Report Q3, 2023 Results on Nov 09, 2023

New major risk - Share price stability

ProSomnus, Inc. announced that it expects to receive $25 million in funding from Spring Mountain Capital, LP and other investors

Prosomnus, Inc. Announces Updated Clinical Trial Data

ProSomnus Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Market Value of Listed Securities Pursuant to Nasdaq Listing Rule 5450(b)(2)(A)

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

ProSomnus, Inc. Announces Cessation of Mark Murphy as Executive Officer

ProSomnus, Inc. to Report Q2, 2023 Results on Aug 03, 2023

First quarter 2023 earnings released: US$0.43 loss per share (vs US$0.12 loss in 1Q 2022)

Full year 2022 earnings released: US$0.71 loss per share (vs US$0.24 loss in FY 2021)

ProSomnus, Inc. Provides Revenue Guidance for the Year Ended December 31, 2022

ProSomnus, Inc. Announces Completion of Enrollment in Antwerp University Hospital’s First Line Obstructive Sleep Apnea Treatment Study (FLOSAT)

ProSomnus, Inc. Enrolls First Participant in Study Evaluating Safety and Efficacy of ProSomnus EVO(TM) in Treating Severe Obstructive Sleep Apnea

No independent directors

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera